TCT-723 Transferring from Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients: High on-Treatment Platelet Reactivity Analysis of the TRIPLET Trial

Jean G. Diodati, Harold Fisher, Dominick J. Angiolillo(University of Florida), Carsten Henneges(Eli Lilly (Germany)), Fred Lipkin(Daiichi Sankyo (United States)), Tracy Cardillo(Eli Lilly (United States)), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Jorge Saucedo, Mark B. Effron(Eli Lilly (United States))
Journal of the American College of Cardiology
October 1, 2012
10.1016/j.jacc.2012.08.764
Cited by 0

Related Papers

Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
|New England Journal of Medicine|2013|825
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
|Circulation|2008|757
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
Platelet Inhibition with Cangrelor in Patients Undergoing PCI
|New England Journal of Medicine|2009|618